Salvianolic acid F
Based on 1 publication(s) in Google Scholar
Salvianolic acid F is a KRAS inhibitor, especially for KRAS G12D. Salvianolic acid F inhibits NF-kB, MMP-9, and NO simultaneously. Salvianolic acid F inhibits cancer cell growth, invasion, and migration and induces apoptosis via the EP300/PI3K/AKT pathway in vitro. Salvianolic acid F inhibits the growth of KRAS-dependent lung cancer cells via the PI3K/AKT signaling pathway in vivo. Salvianolic acid F can be used in the research of various cancers, including KRAS G12D-driven non-small cell lung cancer (NSCLC) and ovarian cancer.
For research use only. We do not sell to patients.
- Purity: 99.49%
- CAS No.: 158732-59-3
- Formula: C17H14O6
- Molecular Weight:314.29
-
Storage:Powder -20°C, 3 years , 4°C, 2 years ; In solvent -80°C, 6 months , -20°C, 1 month
Publications Citing Use of MedChemExpress (MCE) Salvianolic acid F
MoreAll Caspase Isoforms
More
Biological Activity
|
K-RAS |
Caspase 3 |
MMP-9 |
Salvianolic acid F (0-100 μM, 24-72 h) shows cytotoxicity against A549, OE-KRAS A549 cells, with 24 h IC50s of 41.18, 36.55 μM, with 48 h IC50s of 35.17, 29.33 μM, shows cytotoxicity against OVCAR-3, SK-OV-3 OC cells, with IC50s of 28.89, 29.94 µM[1][2].
Salvianolic acid F (0-40 μM, 48 h) inhibits migration and proliferation and promotes apoptosis in OE-KRAS A549, OVCAR-3, SK-OV-3 OC cells[1][2].
Salvianolic acid F (0-40 μM, 48 h) suppresses the EP300/PI3K/AKT signaling pathway in OVCAR-3, SK-OV-3 OC cells[2].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
-
Cell Line:OE-Ctrl, OE-KRAS, shCtrl, and shKRAS A549 cells
-
Concentration:0, 10, 20 µM
-
Incubation Time:48 h
-
Result:Inhibited the in vitro migration of OE-KRAS A549 cells, but had a poorer inhibition on the migration of shKRAS A549 cells at 20 µM.
-
Cell Line:OE-KRAS and shKRAS A549 cells
-
Concentration:0, 10, 20 µM
-
Incubation Time:48 h
-
Result:Induced marked apoptosis in OE-KRAS A549 cells, but showed not obvious apoptosis in shKRAS A549 cells.
-
Cell Line:OVCAR-3, SK-OV-3 OC cells
-
Concentration:0, 20, 40 µM
-
Incubation Time:48 h
-
Result:Significant reduced EdU-positive cells.
-
Cell Line:OVCAR-3, SK-OV-3 OC cells
-
Concentration:0, 20, 40 µM
-
Incubation Time:48 h
-
Result:Inhibited cell migration.
-
Cell Line:OVCAR-3, SK-OV-3 OC cells
-
Concentration:0, 20, 40 µM
-
Incubation Time:48 h
-
Result:Exhibited a significantly elevated apoptosis rate in a dose-dependent manner compared to untreated cells.
Increased caspase-3 cleavage, Bax expression, decreased Bcl-2 expression in a dose-dependent manner compared to control cells.
-
Cell Line:OVCAR-3, SK-OV-3 OC cells
-
Concentration:0, 20, 40 µM
-
Incubation Time:48 h
-
Result:Decreased EP300, p-PI3K/PI3K, Bax/Bcl-2, and cleaved caspase-3/caspase-3 ratios.
Salvianolic acid F (10-20 mg/kg, i.p., every 2 days for 40 days) inhibits lung tumor growth by influencing the downstream PI3K/AKT pathway in KrasG12D mice model[1].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
-
Animal Model:A549 (5 × 106) xenografts nude mice (6 weeks old BALB/c) model[1]
-
Dosage:10, 20 mg/kg
-
Administration:i.p., each day for 15 days
-
Result:Did not induce significant weight loss and began to inhibit tumor growth from day 7 at 20 mg/kg, with no significant inhibitory effect at 10 mg/kg.
Inhibited the expression of KRAS and reduced cell proliferation in mice at 20 mg/kg.
Inhibited AKT phosphorylation, increased the expression of Bax, cleaved-Caspase3 and cleaved-PARP, decreased the expression of Bcl2, promoted apoptosis in lung cancer cells.
-
Animal Model:KrasG12D mice model[1]
-
Dosage:10, 20 mg/kg
-
Administration:i.p., every 2 days for 40 days
-
Result:Not changed body weight, decreased the number and size of lung tumors, reaching 48% and 64% in the 10 mg/kg and 20 mg/kg groups, compared with the control group.
Inhibited KrasG12D expression, inhibited the pathological histomorphology, reduced cell proliferation.
Inhibited AKT phosphorylation, increased the expression of Bax, cleaved-Caspase3 and cleaved-PARP, decreased the expression of Bcl2, promoted apoptosis in lung cancer cells.
Chemical Information
-
CAS No. 158732-59-3
-
Appearance Solid
-
Molecular Weight 314.29
-
Formula C17H14O6
-
Color Light yellow to yellow
-
SMILES
O=C(O)/C=C/C1=CC=C(O)C(O)=C1/C=C/C2=CC=C(O)C(O)=C2
-
Structure Classification
-
Initial Source
-
Shipping
Room temperature in continental US; may vary elsewhere.
-
Storage
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month
Publications (1)
-
Journal Impact Factor
-
Most Recent
-
Cancer Biother Radiopharm
Ultrasound-Enhanced Delivery of Salvianolic Acid F Targets CXCL5 to Suppress Lung Cancer Progression: Insights from In Vitro PC9 and H1299 Models. [Abstract]2025 Sep 10. PMID: 40928959
Solvent & Solubility
DMSO : 100 mg/mL (318.18 mM; Need ultrasonic; Hygroscopic DMSO has a significant impact on the solubility of product, please use newly opened DMSO)
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month. When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month. When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.
Concentration (start) × Volume (start) = Concentration (final) × Volume (final)
Purity & Documentation
-
Data Sheet (283 KB)
-
SDS (251 KB)
- English - EN (251 KB)
- Français - FR (251 KB)
- Deutsch - DE (251 KB)
- Norwegian - NO (251 KB)
- Español - ES (251 KB)
- Swedish - SV (251 KB)
- Italian - IT (251 KB)
- Korean - KR (251 KB)
- Portuguese - PT (251 KB)
-
Handling Instructions (2659 KB)
References
[1]. Hou X, et al. Salvianolic acid F suppresses KRAS-dependent lung cancer cell growth through the PI3K/AKT signaling pathway. Phytomedicine. 2023 Dec;121:155093. [Content Brief]
[2]. Ding C, et al. Preliminary exploration of the potential role of salvianolic acid F in regulating ovarian cancer cell proliferation, migration, invasion, and apoptosis and its association with the EP300/PI3K/AKT pathway. Adv Clin Exp Med. 2025 Apr 16. [Content Brief]
Complete Stock Solution Preparation Table
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month. When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.
| Optional Solvent | Concentration Solvent Mass | 1 mg | 5 mg | 10 mg | 25 mg |
|---|---|---|---|---|---|
| DMSO | 1 mM | 3.1818 mL | 15.9089 mL | 31.8177 mL | 79.5444 mL |
| 5 mM | 0.6364 mL | 3.1818 mL | 6.3635 mL | 15.9089 mL | |
| 10 mM | 0.3182 mL | 1.5909 mL | 3.1818 mL | 7.9544 mL | |
| 15 mM | 0.2121 mL | 1.0606 mL | 2.1212 mL | 5.3030 mL | |
| 20 mM | 0.1591 mL | 0.7954 mL | 1.5909 mL | 3.9772 mL | |
| 25 mM | 0.1273 mL | 0.6364 mL | 1.2727 mL | 3.1818 mL | |
| 30 mM | 0.1061 mL | 0.5303 mL | 1.0606 mL | 2.6515 mL | |
| 40 mM | 0.0795 mL | 0.3977 mL | 0.7954 mL | 1.9886 mL | |
| 50 mM | 0.0636 mL | 0.3182 mL | 0.6364 mL | 1.5909 mL | |
| 60 mM | 0.0530 mL | 0.2651 mL | 0.5303 mL | 1.3257 mL | |
| 80 mM | 0.0398 mL | 0.1989 mL | 0.3977 mL | 0.9943 mL | |
| 100 mM | 0.0318 mL | 0.1591 mL | 0.3182 mL | 0.7954 mL |